KRAS and lung carcinoma: Figure 5 shows the distribution of point mutations by cancer type. Across all cancer types, TP53 (167/367, 45.5%), EGRF (56/367, 15.3%), KRAS (34/337, 9.3%), and BRAC1 (21/337, 5.7%) mutations were common. According to each cancer type, TP53 (120/249, 48.2%), EGFR (51/249, 20.5%), and KRAS (27/249, 10.8%) mutations were common in lung cancer; TP53 (39/70, 55.7%), BRCA1 (9/70, 12.9%), and PIK3CA (5/70, 7.1%) mutations were common in ovarian cancer; and TP53 (3/8, 37.5%), BRCA2 (3/8, 37.5%), and PIK3CA (3/8, 37.5%) mutations were common in breast cancer.